{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T19:07:09Z","timestamp":1677438429937},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T00:00:00Z","timestamp":1337644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s10840-012-9677-2","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T04:25:42Z","timestamp":1337574342000},"page":"19-27","source":"Crossref","is-referenced-by-count":1,"title":["Prevention of stroke in patients with atrial fibrillation"],"prefix":"10.1007","volume":"35","author":[{"given":"Christopher J.","family":"Varughese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,22]]},"reference":[{"key":"9677_CR1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinte.1995.00430050045005","volume":"155","author":"WM Feinberg","year":"1995","unstructured":"Feinberg, W. M., Blackshear, J. L., Laupacis, A., Kronmal, R. A., & Hart, R. G. (1995). Prevalence age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Archives of Internal Medicine, 155, 469\u2013473.","journal-title":"Archives of Internal Medicine"},{"issue":"18","key":"9677_CR2","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., et al. (2001). Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk factors in Atrial fibrillation (ATRIA) study. Journal of the American Medical Association, 285(18), 2370\u20132375.","journal-title":"Journal of the American Medical Association"},{"issue":"6","key":"9677_CR3","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","volume":"36","author":"C Marini","year":"2005","unstructured":"Marini, C., De Santis, F., Sacco, S., Russo, T., Olivieri, C., Totaro, R., et al. (2005). Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: Results from a population-based study. Stroke, 36(6), 1115\u20131119.","journal-title":"Stroke"},{"issue":"10","key":"9677_CR4","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","volume":"27","author":"HJ Lin","year":"1996","unstructured":"Lin, H. J., Wolf, P. A., Kelly-Hayes, M., Beiser, A. S., Kase, C. S., Benjamin, E. J., et al. (1996). Stroke severity in atrial fibrillation; the Framingham study. Stroke, 27(10), 1760\u20131764.","journal-title":"Stroke"},{"issue":"11","key":"9677_CR5","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/eurheartj\/ehp124","volume":"30","author":"M Bohm","year":"2009","unstructured":"Bohm, M., Thoenes, M., Neuberger, H. R., Graber, S., Rell, J. C., Bramlage, P., et al. (2009). Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. European Heart Journal, 30(11), 1364\u20131371.","journal-title":"European Heart Journal"},{"issue":"12","key":"9677_CR6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"R Hart","year":"2007","unstructured":"Hart, R., Pearce, L. A., & Aguilar, M. I. (2007). Meta-analysis: Anti-thrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine, 146(12), 857\u2013867.","journal-title":"Annals of Internal Medicine"},{"key":"9677_CR7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/01.STR.0000208294.46968.a4","volume":"37","author":"E Birman-Deych","year":"2006","unstructured":"Birman-Deych, E., Radford, M. J., Nilasena, D. S., & Gage, B. F. (2006). Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke, 37, 1070\u20131074.","journal-title":"Stroke"},{"issue":"8899","key":"9677_CR8","first-page":"687","volume":"343","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1994","unstructured":"Stroke Prevention in Atrial Fibrillation Investigators. (1994). Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: SPAF II Study. Lancet, 343(8899), 687\u2013691.","journal-title":"Lancet"},{"issue":"9586","key":"9677_CR9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","volume":"370","author":"J Mant","year":"2007","unstructured":"Mant, J., Hobbs, F. D., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., et al. (2007). BAFTA investigators. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet, 370(9586), 493\u2013503.","journal-title":"Lancet"},{"issue":"7","key":"9677_CR10","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/01.STR.0000170642.39876.f2","volume":"36","author":"RG Hart","year":"2005","unstructured":"Hart, R. G., Silvina, T. B., Tonarelli, M. D., Lesly, A., & Pearce, M. S. (2005). Avoiding central nervous system bleeding during antithrombotic therapy. Stroke, 36(7), 1588\u20131593.","journal-title":"Stroke"},{"issue":"3 Suppl","key":"9677_CR11","doi-asserted-by":"crossref","first-page":"429S","DOI":"10.1378\/chest.126.3_suppl.429S","volume":"126","author":"DE Singer","year":"2004","unstructured":"Singer, D. E., Albers, G. W., Dalen, J. E., Go, A. S., Halperin, J. L., & Manning, W. J. (2004). Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126(3 Suppl), 429S\u2013456S.","journal-title":"Chest"},{"issue":"12","key":"9677_CR12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.105.553438","volume":"112","author":"MC Fang","year":"2005","unstructured":"Fang, M. C., Singer, D. E., Chang, Y., Hylek, E. M., Henault, L. E., Jensvold, N. G., et al. (2005). Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation, 112(12), 1687\u20131691.","journal-title":"Circulation"},{"issue":"8","key":"9677_CR13","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.163.8.936","volume":"163","author":"C Walraven Van","year":"2003","unstructured":"Van Walraven, C., Hart, R. G., Wells, G. A., Petersen, P., Koudstaal, P. J., Gullov, A. L., et al. (2003). Clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Archives of Internal Medicine, 163(8), 936\u2013943.","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"9677_CR14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ahj.2008.06.029","volume":"156","author":"S Goto","year":"2008","unstructured":"Goto, S., Bhatt, D. L., R\u00f6ther, J., Alberts, M., Hill, M., Ikeda, Y., et al. (2008). Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. American Heart Journal, 156(5), 855\u2013863.","journal-title":"American Heart Journal"},{"key":"9677_CR15","doi-asserted-by":"crossref","first-page":"d142","DOI":"10.1136\/bmj.d142","volume":"342","author":"JB Olesen","year":"2011","unstructured":"Olesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., et al. (2011). Valdiation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. British Medical Journal, 342, d142.","journal-title":"British Medical Journal"},{"issue":"6","key":"9677_CR16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.amjmed.2009.12.013","volume":"123","author":"GY Lip","year":"2010","unstructured":"Lip, G. Y., & Halperin, J. L. (2010). Improving stroke risk stratification in atrial fibrillation. American Journal of Medicine, 123(6), 484\u2013488.","journal-title":"American Journal of Medicine"},{"issue":"2","key":"9677_CR17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest, 137(2), 263\u2013272.","journal-title":"Chest"},{"issue":"12","key":"9677_CR18","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","volume":"41","author":"GY Lip","year":"2010","unstructured":"Lip, G. Y., Frison, L., Halperin, J. L., & Lane, D. A. (2010). Identifying patients at high risk for stroke despite anticoagulation: A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke, 41(12), 2731\u20132738.","journal-title":"Stroke"},{"issue":"3","key":"9677_CR19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","volume":"151","author":"BF Gage","year":"2006","unstructured":"Gage, B. F., Yan, Y., Milligan, P. E., Waterman, A. D., Culverhouse, R., Rich, M. W., et al. (2006). Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). American Heart Journal, 151(3), 713\u2013719.","journal-title":"American Heart Journal"},{"issue":"2","key":"9677_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","volume":"105","author":"RJ Beyth","year":"1998","unstructured":"Beyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998). Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. American Journal of Medicine, 105(2), 91\u201399.","journal-title":"American Journal of Medicine"},{"issue":"5","key":"9677_CR21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters, R., Lane, D. A., Niewlatt, R., DeVos, C. B., Crinjs, H. J., & Lip, G. Y. (2010). A novel user- friendly score (HAS BLED) to assess one year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest, 138(5), 1093\u20131110.","journal-title":"Chest"},{"issue":"9397","key":"9677_CR22","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","volume":"362","author":"SB Olsson","year":"2003","unstructured":"Olsson, S. B., & Executive Steering Committee of the SPORTIF III Investigators. (2003). Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomized controlled trial. Lancet, 362(9397), 1691\u20131698.","journal-title":"Lancet"},{"issue":"6","key":"9677_CR23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","volume":"293","author":"GW Albers","year":"2005","unstructured":"Albers, G. W., Diener, H. C., Frison, L., Grind, M., Nevinson, M., Partrdige, S., et al. (2005). Ximelagatran vs. warfarin for stroke prevention in patients with non-valvular atrial fibrillation: A randomized trial. Journal of the American Medical Association, 293(6), 690\u2013698.","journal-title":"Journal of the American Medical Association"},{"issue":"2","key":"9677_CR24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"GY Lip","year":"2010","unstructured":"Lip, G. Y., Frison, L., Halperin, J. L., & Lane, D. A. (2010). Comparative validation of a novel risk score [HAS-BLED] for predicting bleeding risk in anticoagulated patients with atrial fibrillation. Journal of the American College of Cardiology, 57(2), 173\u2013180.","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"9677_CR25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacc.2010.09.026","volume":"57","author":"SH Hohnloser","year":"2011","unstructured":"Hohnloser, S. H. (2011). Stroke prevention versus bleeding risk in atrial fibrillation: A clinical dilemma. Journal of the American College of Cardiology, 57(2), 181\u2013183.","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"9677_CR26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"GY Lip","year":"2011","unstructured":"Lip, G. Y., Frison, L., Halperin, J. L., & Lane, D. A. (2011). Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. The HAS BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, elderly, Drugs\/Alcohol Concomitantly) Score. Journal of the American College of Cardiology, 57(2), 173\u2013180.","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"9677_CR27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","volume":"58","author":"MC Fang","year":"2011","unstructured":"Fang, M. C., Go, A. S., Chang, Y., Borowsky, L. H., Pmernacki, N. K., Udaltsova, N., et al. (2011). A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (anti-coagulation and risk factors in Atrial Fibrillation) Study. Journal of the American College of Cardiology, 58(4), 395\u2013401.","journal-title":"Journal of the American College of Cardiology"},{"issue":"20","key":"9677_CR28","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","volume":"360","author":"SJ Connolly","year":"2009","unstructured":"Connolly, S. J., Pogue, J., Hohnloser, H., Pfeffer, M., Chrolavicius, S., Yusuf, S., et al. (2009). ACTIVE investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England Journal of Medicine, 360(20), 2066\u20132078.","journal-title":"The New England Journal of Medicine"},{"issue":"9526","key":"9677_CR29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"SJ Connolly","year":"2006","unstructured":"Connolly, S. J., Pogue, J., Hohnloser, H., Pfeffer, M., Chrolavicius, S., Yusuf, S., et al. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomized controlled trial. Lancet, 367(9526), 1903\u20131912.","journal-title":"Lancet"},{"issue":"12","key":"9677_CR30","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361(12), 1139\u20131151.","journal-title":"The New England Journal of Medicine"},{"issue":"19","key":"9677_CR31","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","volume":"363","author":"SJ Connolly","year":"2010","unstructured":"Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010). Newly identified events in the RE-LY trial. The New England Journal of Medicine, 363(19), 1875\u20131876.","journal-title":"The New England Journal of Medicine"},{"key":"9677_CR32","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","volume":"364","author":"N Beasley","year":"2011","unstructured":"Beasley, B. N., Unger, E. F., & Temple, R. (2011). Anticoagulant options\u2014why the FDA approved a higher but not a lower dose of dabigatran. The New England Journal of Medicine, 364, 1788\u20131790.","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"9677_CR33","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/ATVBAHA.110.203604","volume":"30","author":"WG Eisert","year":"2010","unstructured":"Eisert, W. G., Hauel, N., Stangier, J., Wienen, W., Clemens, A., & van Ryn, J. (2010). Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombin. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(10), 1885\u20131889.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"13","key":"9677_CR34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","volume":"123","author":"GJ Hankey","year":"2011","unstructured":"Hankey, G. J., & Eikelboom, J. W. (2011). Dabigatran etexilate: A new oral thrombin inhibitor. Circulation, 123(13), 1436\u20131450.","journal-title":"Circulation"},{"issue":"10","key":"9677_CR35","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/CIR.0b013e31820f14c0","volume":"123","author":"LS Wann","year":"2011","unstructured":"Wann, L. S., Curtis, A. B., Ellenbogen, K. A., Estes, N. A., 3rd, Ezekowitz, M. D., Jackman, W. M., et al. (2011). ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation, 123(10), 1144\u20131150.","journal-title":"Circulation"},{"key":"9677_CR36","doi-asserted-by":"crossref","unstructured":"Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation: The ROCKET AF trial. The New England Journal of Medicine, 365, 883\u2013891.","DOI":"10.1056\/NEJMoa1009638"},{"key":"9677_CR37","unstructured":"Connolly, S. (2010). AVERROES: Primary and secondary endpoints. Presented at the European Society of Cardiology 2010 Congress, August 31; Stockholm, Sweden."},{"issue":"11","key":"9677_CR38","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. H., Hanna, M., et al. (2011). Apixiban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 365(11), 981\u2013992.","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"9677_CR39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"CT Ruff","year":"2010","unstructured":"Ruff, C. T., Giugliano, R. P., Antman, E. M., Crugnale, S. E., Bocanegra, T., Mercuri, N., et al. (2010). Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). American Heart Journal, 160(8), 635\u2013641.","journal-title":"American Heart Journal"},{"key":"9677_CR40","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1161\/CIRCULATIONAHA.110.973735","volume":"122","author":"MD Ezekowitz","year":"2010","unstructured":"Ezekowitz, M. D., Wallentin, L., Connolly, S. J., Parekh, A., Chernick, M. R., Pogue, J., et al. (2010). Dabigatran and warfarin in vitamin K antagonist-na\u00efve and experienced cohorts with atrial fibrillation. Circulation, 122, 2246\u20132253.","journal-title":"Circulation"},{"key":"9677_CR41","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/CIR.0b013e31820f14c0","volume":"123","author":"LS Wann","year":"2011","unstructured":"Wann, L. S., Curtis, A. B., Ellenbogen, K. A., Estes, N. A., III, Ezekowitz, M. D., Jackman, W. M., et al. (2011). ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation, 123, 1144\u20131150.","journal-title":"Circulation"},{"key":"9677_CR42","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","volume":"124","author":"ES Erenberg","year":"2011","unstructured":"Erenberg, E. S., Kamphuisen, P. W., Sijpkens, M. E., Meijers, J. C., Buller, H. R., & Levi, M. (2011). Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 124, 1573\u20131579.","journal-title":"Circulation"},{"key":"9677_CR43","first-page":"A94","volume":"37","author":"J Ryn Van","year":"2010","unstructured":"Van Ryn, J., Dorr, B., Kaspereit, F., Krege, W., Zeitler, S., & Pragst, I. (2010). Beriplex P\/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits (presented at the 21st Internal Congress on Thrombosis) [abstract]. Pathophysiology of Haemostasis and Thrombosis, 37, A94\u2013P486.","journal-title":"Pathophysiology of Haemostasis and Thrombosis"},{"issue":"3","key":"9677_CR44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","volume":"107","author":"A Banerjee","year":"2012","unstructured":"Banerjee, A., Lane, D. A., Torp-Pedersen, T., & Lip, G. Y. H. (2012). Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixiban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Thrombosis and Haemostasis, 107(3), 584\u2013589.","journal-title":"Thrombosis and Haemostasis"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-012-9677-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10840-012-9677-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-012-9677-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T23:04:40Z","timestamp":1561763080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10840-012-9677-2"}},"subtitle":["Anticoagulant and antiplatelet options"],"short-title":[],"issued":{"date-parts":[[2012,5,22]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["9677"],"URL":"https:\/\/doi.org\/10.1007\/s10840-012-9677-2","relation":{},"ISSN":["1383-875X","1572-8595"],"issn-type":[{"value":"1383-875X","type":"print"},{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,22]]}}}